Pediatrik Üveitler

Yıl 2018, Cilt: 16 Sayı: 2, 230 - 246, 01.08.2018

Tuba Çelik

Öz

Pediatrik üveitler, farklı kliniklerde ortaya çıkması, ambliyopi riski ve tedavi yönetimindeki kısıtlılıklar nedeniyle klinisyenler için önemli bir yere sahiptir. Çocukluk çağındaki üveitler genellikle rutin göz muayenesi sırasında tespit edilmekte ve tedavi seçeneklerinin kısıtlı olması nedeniyle ciddi komplikasyonlara neden olabilmektedir. Hastalar inflamasyona tolerans geliştirmesi için beklenilen dönemde ya da suboptimal tedavi ile takip edildikleri dönemde glokom, katarakt, ambliyopi ve bant keratopati gibi ciddi komplikasyonlarla karşı karşıya kalmaktadır. Bu derlemede, çocukluk çağındaki başlıca üveit sebepleri ve tedavi yaklaşımları ele alınmıştır.

Anahtar Kelimeler

pediatrik, çocukluk çağı, üveit

Kaynakça

• 1. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol. 2003;135:676–80.
• 2. Zierhut M, Michels H, Stübiger N, Besch D, Deuter C, Heiligenhaus A. Uveitis in children. Int Ophthalmol Clin. 2005;45:135–56.
• 3. Majumder PD, Biswas J. . Pediatric uveitis: An update.Oman J Ophthalmol. 2013;6:140-50.
• 4. Kadayifçilar S, Eldem B, Tumer B. Uveitis in childhood. J Pediatr Ophthalmol Strabismus. 2003;40:335-40.
• 5. Chalom EC, Goldsmith DP, Koehler MA, Bittar B, Rose CD, Ostrov BE, Keenan GF. Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. J Rheumatol. 1997;24:2031a4.
• 6. Rauz S, Murray PI, Southwood TR. Juvenile idiopathic arthritis and uveitis: The classification conundrum. Eye (Lond) 2000;14:817–20.
• 7. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104:236-44.
• 8. Keenan JD, Goldstein DA, Tessler HH. Granulomatous inflammation in Juvenile Idiopathis Arthritis. J AAPOS. 2008;12:546–50.
• 9. Boone MI, Moore TL, Cruz OA. Screening for uveitis in juvenile rheumatoid arthritis. J Pediatr Ophthalmol Strabismus. 1998;35:41–3.
• 10. Brunner HI, Kim KN, Ballinger SH, Bowyer SL, Griffin TA, Higgins GC, Mier R et al. Current medication choices in Juvenile Rheumatoid Arthritis II -update of a survey performed in 1993. J Clin Rheumatol.2001;7:295.
• 11. Ravelli A, Moretti C, Temporini F, Rossi F, Magni-Manzoni S, Pistorio A, Martini A. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:569–72.
• 12. Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Efficacy and safety of chlorambucil in intractable noninfectious uveitis. Ophthalmology. 2002;109:137–42.
• 13. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–24.
• 14. Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni PL, Gerloni V. Rituximab for uveitis.Ophthalmology. 2011;118:223–4.
• 15. Maris K, Van Calster J, Wouters C, Casteels I. Clinical symptoms and complications of pars planitis in childhood. Bull Soc Belge Ophtalmol. 2005;(295):29-33.
• 16. Romero R, Peralta J, Sendagorta E, Abelairas J. Pars planitis in children: epidemiologic, clinical, and therapeutic characteristics. J Pediatr Ophthalmol Strabismus. 2007;44(5):288-93.
• 17. Serna-Ojeda JC, Pedroza-Seres M. Treatment with immunosuppressive therapy in patients with pars planitis: experience of a reference centre in Mexico. Br J Ophthalmol. 2014;98:1503-7.
• 18. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behcet's disease: An international collaborative study. Br J Ophthalmol. 2007;91:1579–82.
• 19. Koné-Paut I, Gorchakoff-Molinas A, Weschler B, Touitou I. Paediatric Behcet's disease in France. Ann Rheum Dis. 2002;61:655–6.
• 20. Evereklioglu C. Current Concepts in the Etiology and Treatment of Behçet's Disease. Surv Ophthalmol.2005;50:297–350.
• 21. Criteria for diagnosis of BehrmatologyTwentyh Behcet's patients. Int J Dermatolor = true and cauthor_uid. 1990;335:1078–80.
• 22. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behcet's disease: An international collaborative study. Br J Ophthalmol. 2007;91:1579–82.
• 23. Zakka FR, Chang PY, Giuliari GP, Foster CS. Current trends in the management of ocular symptoms in Adamantiades-Behcet's disease. Clin Ophthalmol. 2009;3:567–79.
• 24. Gedalia A, Khan TA, Shetty AK, Dimitriades VR, Espinoza LR. Childhood sarcoidosis: Louisiana experience. Clin Rheumatol. 2015 Jan 24.
• 25. El Hansali Z, Oukabli M, Laktaoui A, Kriet M, Oubaaz A, Chana H. Childhood sarcoidosis: ophthalmological manifestations and diagnostic difficulties in two cases. J Fr Ophtalmol. 2012:290.e1-5.
• 26. Kawaguchi T, Hanada A, Horie S, Sugamoto Y, Sugita S, Mochizuki M. Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis. Jpn J Ophthalmol. 2007;51:121–6.
• 27. Bhat P, Cervantes-Castañeda RA, Doctor PP, Anzaar F, Foster CS. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm. 2009;17:185-90.
• 28. Kumar K, Mathai A, Murthy SI, Jalali S, Sangwan V, Reddy Pappuru R, Pathangay A. Sympathetic ophthalmia in pediatric age group: clinical features and challenges in management in a tertiary center in southern India. Ocul Immunol Inflamm. 2014;22:367-72.
• 29. Chu XK, Chan CC. Sympathetic ophthalmia: to the twenty-first century and beyond. J Ophthalmic Inflamm Infect. 2013;3:49.
• 30. Chang GC, Young LH. Sympathetic ophthalmia. Semin Ophthalmol. 2011;26:316-20.
• 31. Arevalo JF, Garcia RA, Al-Dhibi HA, Sanchez JG, Suarez-Tata L. Update on sympathetic ophthalmia. Middle East Afr J Ophthalmol. 2012;19:13-21.
• 32. Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol. 2011;129:250-2.
• 33. Benfdil N, Baha Ali T, Jellab B, Moutaouakil A. Vogt Koyanagi Harada syndrome in children: diagnosis and management. Bull Soc Belge Ophtalmol. 2010;314:15-8.
• 34. García LA, Carroll MO, Garza León MA. Vogt-Koyanagi-Harada syndrome in childhood. Int Ophthalmol Clin. 2008;48:107-17.
• 35. Khalifa YM, Bailony MR, Acharya NR. Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab. Ocul Immunol Inflamm. 2010;18:218-22.
• 36. Mackensen F, Billing H. Tubulointerstitial nephritis and uveitis syndrome. Curr Opin Ophthalmol. 2009;20:525-31.
• 37. Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Opthalmol. 2001;46:195D–46. 1.
• 38. Paladini A, Venturoli V, Mosconi G, Zambianchi L, Serra L, Valletta E. Tubulointerstitial nephritis and uveitis syndrome in a twelve-year-old girl. Case Rep Pediatr. 2013;2013:652043.
• 39. Maenz M, Schlüter D, Liesenfeld O, Schares G, Gross U, Pleyer U. Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res. 2014;39:77-106.
• 40. Holland GN. Ocular toxoplasmosis: A global reassessment. Part II: Disease manifestations and management. Am J Ophthalmol. 2004;137:137.
• 41. Harrell M, Carvounis PE. Current treatment of toxoplasma retinochoroiditis: an evidence-based review. J Ophthalmol. 2014;2014:273506.
• 42. Roberts F, Mets MB, Ferguson DJ, O’Grady R, O’Grady C, Thulliez P, et al. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch Ophthalmol. 2001;119:51–8.
• 43. Bessie’res MH, Roques C, Berrebi A, Barre V, Cazaux M, Seguela J. IgA antibody response during acquired and congenital toxoplasmosis. J Clin Pathol. 1992;45:605–8.
• 44. Dworkin LL, Gibler TM, Van Gelder RN. Real-time quantitative polymerase chain reaction diagnosis of infectious posterior uveitis. Arch Ophthalmol. 2002;120:1534–9.
• 45. Silveira C, Belfort R, Jr, Muccioli C, Holland GN, Victora CG, Horta BL, et al. The effect of longterm intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134:4146.
• 46. Rothova A, Bosch-Driessen LE, van Loon NH, Treffers WF. Azithromycin for ocular toxoplasmosis. Br J Ophthalmol. 1998;82:130688.
• 47. de-la-Torre A, Stanford M, Curi A, Jaffe GJ, Gomez-Marin JE. Therapy for ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19:314-20.
• 48. Woodhall D, Starr MC, Montgomery SP, Jones JL, Lum F, Read RW, Moorthy RS. Ocular toxocariasis: epidemiologic, anatomic, and therapeutic variations based on a survey of ophthalmic subspecialists. Ophthalmology. 2012;119:1211-7.
• 49. Deuter CM, Garweg JG, Pleyer U, Schönherr U, Thurau S. Ocular toxoplasmosis and toxocariasis in childhood. Klin Monbl Augenheilkd. 2007;224:483-7.
• 50. Yokoi K, Goto H, Sakai J, Usui M. Clinical features of ocular toxocariasis in Japan. Ocul Immunol Inflamm. 2003;11:269–75.
• 51. Shields JA, Parsons HM, Shields CL, Shah P. Lesions simulating retinoblastoma. J Pediatr Ophthalmol Strabismus. 1991;28:338–40.
• 52. de Visser L, Rothova A, de Boer JH, van Loon AM, Kerkhoff FT, Canninga-van Dijk MR, et al. Diagnosis of ocular toxocariasis by establishing intraocular antibody production. Am J Ophthalmol.2007;145:369–74.
• 53. Barisani-Asenbauer T, Maca SM, Hauff W, Kaminski SL, Domanovits H, Theyer I, Auer H. Retreatment of ocular toxocariasis with albendazole. J Ocul Pharmacol Ther. 2001;17:287-94.
• 54. Roy R, Pal BP, Mathur G, Rao C, Das D, Biswas J. Acute retinal necrosis: clinical features, management and outcomes--a 10 year consecutive case series. Ocul Immunol Inflamm. 2014;22:170-4.
• 55. Chiquet C, Bodaghi B, Mougin C, Najioullah F. Acute retinal necrosis diagnosed in a child with chronic panuveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:1206-8.
• 56. Muthiah MN, Michaelides M, Child CS, Mitchell SM. Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK. Br J Ophthalmol. 2007;91:1452-5.
• 57. Tibbetts MD, Shah CP, Young LH, Duker JS, Maguire JI, Morley MG. Treatment of acute retinal necrosis. Ophthalmology. 2010;117:818-24.
• 58. Kishore K, Jain S, Zarbin MA. Intravitreal ganciclovir and dexamethasone as adjunctive therapy in the management of acute retinal necrosis caused by varicella zoster virus. Ophthalmic Surg Lasers Imaging. 2011;42:e87-90.
• 59. Tran TH, Rozenberg F, Fillet AM, Bodaghi B. Diagnostic and therapeutic management of a severe acyclovir-resistant acute retinal necrosis in a young child. Graefes Arch Clin Exp Ophthalmol. 2005;243:266-8.
• 60. Gupta V, Gupta A, Rao NA. Intraocular tuberculosis. An update. Surv Ophthalmol. 2007;52:561–87.
• 61. Burgoyne CF, Verstraeten TC, Friberg TR. Tuberculin skin–test induced uveitis in the absence of tuberculosis. Graefes Arch Clin Exp Ophthalmol. 1991;229:232–6.
• 62. Khan S, Athwal L, Zarbin M, Bhagat N. Pediatric infectious endophthalmitis: a review. J Pediatr Ophthalmol Strabismus. 2014;51:140-53.
• 63. Vaziri K, Schwartz SG, Kishor K, Flynn HW Jr. Endophthalmitis: state of the art. Clin Ophthalmol. 2015;9:95-108.
• 64. Grange LK, Kouchouk A, Dalal MD, Vitale S, Nussenblatt RB, Chan CC, Sen HN. Neoplastic masquerade syndromes in patients with uveitis. Am J Ophthalmol. 2014 Mar;157(3):526-31.
• 65. Gordon KB, Rugo HS, Duncan JL, Irvine AR, Howes EL, Jr, O’Brien JM, et al. Ocular manifestations of leukemia: Leukemic infiltration versus infectious process. Ophthalmology. 2001;108:2293–300.
• 66. All-Ericsson C, Economou MA, Landau I, Träisk F, Seregard S. Uveitis masquerade syndromes: diffuse retinoblastoma in an older child. Acta Ophthalmol Scand. 2007;85:569-70.
• 67. Zamir E, Wang RC, Krishnakumar S, Aiello Leverant A, Dugel PU, Rao NA. Juvenile xanthogranuloma masquerading as pediatric chronic uveitis: A clinicopathologic study. Surv Ophthalmol.2001;46:164–71